WallStSmart

Biodesix Inc (BDSX)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 48118% more annual revenue ($46.34B vs $96.10M). TMO leads profitability with a 15.0% profit margin vs -33.3%. TMO earns a higher WallStSmart Score of 60/100 (C+).

BDSX

Avoid

29

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 4.0Quality: 4.5
Piotroski: 4/9Altman Z: -7.79

TMO

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 3.3Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDSXSignificantly Overvalued (-15.9%)

Margin of Safety

-15.9%

Fair Value

$8.93

Current Price

$23.50

$14.57 premium

UndervaluedFair: $8.93Overvalued
TMOSignificantly Overvalued (-68.2%)

Margin of Safety

-68.2%

Fair Value

$343.49

Current Price

$580.02

$236.53 premium

UndervaluedFair: $343.49Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDSX1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
42.3%10/10

Revenue surging 42.3% year-over-year

TMO2 strengths · Avg: 9.0/10
Market CapQuality
$208.81B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

BDSX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$221.51M3/10

Smaller company, higher risk/reward

Price/BookValuation
26.1x2/10

Trading at 26.1x book value

Return on EquityProfitability
-349.9%2/10

ROE of -349.9% — below average capital efficiency

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.874/10

Expensive relative to growth rate

P/E RatioValuation
30.4x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BDSX

The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 42.3% demonstrates continued momentum.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.

Bear Case : BDSX

The primary concerns for BDSX are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 7.84 is elevated, increasing financial risk.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

BDSX profiles as a hypergrowth stock while TMO is a value play — different risk/reward profiles.

TMO carries more volatility with a beta of 0.85 — expect wider price swings.

BDSX is growing revenue faster at 42.3% — sustainability is the question.

TMO generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (60/100 vs 29/100) and 10.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Biodesix Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?